Aristotle Capital Boston LLC Decreases Holdings in Pediatrix Medical Group, Inc. $MD

Aristotle Capital Boston LLC cut its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 9.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 440,063 shares of the company’s stock after selling 43,922 shares during the period. Aristotle Capital Boston LLC owned about 0.51% of Pediatrix Medical Group worth $9,413,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. PNC Financial Services Group Inc. raised its stake in Pediatrix Medical Group by 4.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 14,525 shares of the company’s stock valued at $243,000 after buying an additional 631 shares during the last quarter. Gotham Asset Management LLC increased its stake in shares of Pediatrix Medical Group by 0.6% in the 3rd quarter. Gotham Asset Management LLC now owns 116,093 shares of the company’s stock worth $1,945,000 after purchasing an additional 724 shares in the last quarter. ProShare Advisors LLC increased its stake in shares of Pediatrix Medical Group by 4.6% in the 4th quarter. ProShare Advisors LLC now owns 16,816 shares of the company’s stock worth $360,000 after purchasing an additional 734 shares in the last quarter. Verition Fund Management LLC increased its stake in shares of Pediatrix Medical Group by 4.4% in the 3rd quarter. Verition Fund Management LLC now owns 25,408 shares of the company’s stock worth $426,000 after purchasing an additional 1,066 shares in the last quarter. Finally, EP Wealth Advisors LLC increased its stake in shares of Pediatrix Medical Group by 5.5% in the 2nd quarter. EP Wealth Advisors LLC now owns 22,579 shares of the company’s stock worth $324,000 after purchasing an additional 1,180 shares in the last quarter. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Shirley A. Weis sold 36,028 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total value of $855,665.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.80% of the company’s stock.

Pediatrix Medical Group Trading Down 2.5%

Shares of MD stock opened at $23.56 on Thursday. Pediatrix Medical Group, Inc. has a 52-week low of $11.84 and a 52-week high of $24.99. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.33 and a current ratio of 1.33. The firm has a market capitalization of $1.93 billion, a PE ratio of 11.44 and a beta of 0.69. The stock has a fifty day simple moving average of $22.58 and a two-hundred day simple moving average of $21.70.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a return on equity of 19.94% and a net margin of 9.02%.The business had revenue of $476.20 million during the quarter, compared to analyst estimates of $465.83 million. During the same quarter in the prior year, the business posted $0.33 EPS. Pediatrix Medical Group’s revenue for the quarter was up 3.9% compared to the same quarter last year. On average, analysts predict that Pediatrix Medical Group, Inc. will post 2.1 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Friday, March 27th. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on Pediatrix Medical Group in a research note on Friday, February 20th. Jefferies Financial Group restated a “buy” rating and issued a $27.00 price objective on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Mizuho set a $24.00 price objective on Pediatrix Medical Group in a research note on Friday, May 8th. Finally, UBS Group upped their price objective on Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $22.50.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.